California Institute of Technology

Absci Advances in AI-Driven Drug Development and Pipeline Updates at 2024 R&D Day

5 months ago

Absci showcased significant progress in its proprietary drug pipeline and AI platform at the 2024 R&D Day, highlighting advancements in treatments for androgenic alopecia, immuno-oncology, and HIV vaccine research, alongside a breakthrough in AI-designed antibodies.

Intellia Therapeutics' Q3 Report Highlights NTLA-2001 and NTLA-2002 Phase II Results

6 months ago

• Intellia Therapeutics' Q3 earnings report emphasizes the significance of Phase II results for NTLA-2001 and NTLA-2002, critical for future stock performance. • NTLA-2001 and NTLA-2002 are high-risk, high-reward investments, with potential for substantial stock rally or decline based on trial outcomes. • Analyst maintains a long position in NTLA, reflecting confidence in the potential success of NTLA-2001 and NTLA-2002 despite inherent risks.

Mosaic-8b Nanoparticle Vaccine Shows Promise Against Sarbecovirus Variants

7 months ago

• A novel mosaic-8b nanoparticle vaccine is under development to provide broad cross-reactive immunity against known and future sarbecovirus strains, enhancing pandemic preparedness. • The vaccine targets conserved regions of the receptor-binding domain (RBD) shared by all SARS-like betacoronaviruses, aiming to overcome the limitations of current vaccines due to viral mutations. • Pre-clinical research indicates the mosaic-8b vaccine triggers robust immune responses, even after prior SARS-CoV-2 exposure, generating broadly cross-reactive antibodies. • Engineering biology CRDMO Ingenza has partnered with other organizations to formulate the vaccine, utilizing microbial platforms to reduce development time and costs.

Summit Therapeutics' Phase III Trial Bests Merck's Keytruda in Lung Cancer

8 months ago

• Summit Therapeutics' SMT-i100 demonstrated superior efficacy compared to Keytruda in a Phase III trial for non-small cell lung cancer (NSCLC). • The study highlighted SMT-i100's potential as a novel therapeutic option, particularly in patients with PD-L1 negative or low expressing tumors. • These results suggest a significant advancement in lung cancer treatment, offering hope for improved outcomes in a challenging patient population.